Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 13, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions. The only financial figures disclosed are the transaction prices for the notional re-investment of dividends: GBP 13.35 per Ordinary Share and $48.00 per Ordinary Share ADR.
Material Changes
The filing details an increase in notional interests in Ordinary Shares and ADRs for various company officials following the re-investment of dividends paid on October 6, 2005. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Key Facts for Investor Verification
- The filing reports specific share plan transactions for 14 individuals, including Mr. R Bondy, Dr. W Calhoun, and Mr. A Witty.
- Transactions involved the notional re-investment of dividends at a price of GBP 13.35 per share and $48.00 per ADR.
- This report is a compliance notification under Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) and does not contain financial performance data.
- The document was signed by Victoria Llewellyn as the Authorised Signatory on October 13, 2005.